Fennec Pharmaceuticals' fourth-quarter Pedmark revenue of US$7.9 million beat Wedbush's US$7.6 million estimate. Initiatives are in place to drive Pedmark growth, including the continued penetration of the adolescent and young adult (AYA) population.
Management commentary on early AYA adoption is encouraging, given that the community treated AYA population is a larger and more lucrative (due to higher dosing and higher reimbursement rates) patient population compared to the in-patient pediatric population, Wedbush said.
Fennec expects its growth initiatives to result in a significant inflection beginning in the second half of this year. Outside the U.S., partner Norgine recently launched Pedmarqsi in the UK and Germany.
Topline data from the Japanese trial of Pedmark in children and AYAs are expected in the second half of this year with a potential registration or licensing deal in Japan to follow. In Turkey and Gulf Cooperation Council Countries, Fennec has partnered with distributor Inpharmus.
Fennec is rated Outperform, with a US$13 target.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.